Kuros Biosciences AG Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 25 Fair Values set on narratives written by author
KURN Community Narratives
Minimally Invasive Spine Procedures And Global Expansion Will Drive Long-Term Opportunity
Minimally Invasive Spine Procedures And Global Expansion Will Drive Long-Term Opportunity
View narrativeTrending Discussion
No trending discussion available.
Recently Updated Narratives
Minimally Invasive Spine Procedures And Global Expansion Will Drive Long-Term Opportunity
Snowflake Analysis
Kuros Biosciences AG Key Details
About KURN
- Founded
- 2016
- Employees
- 178
- CEO
- Website
View website
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Granules, an advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.